Precision Medicine in Oncology®

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.